Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors demonstrated a nearly 50% lower risk for systemic autoimmune rheumatic disease vs. those who received dipeptidyl ...
Asianet Newsable on MSN
GLP-1 medications explained: Benefits, risks and common misconceptions
In recent years, GLP-1 receptor agonists have revolutionised discussions of weight reduction and diabetes management. Type 2 ...
Avoid unnecessary tests and antibiotics by applying evidence-based, cost-conscious infectious-disease decision-making, with ...
This article is authored by Dr Vanita Arora, senior consultant & clinical lead, electrophysiology, cardiac sciences, Indraprastha Apollo Hospitals, Delhi.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results